ASH Meeting 2021 Participation

Scientific Session
Wednesday, December 8
2:00 – 2:45 PM
Location: Georgia World Congress Center, Georgia Ballroom 1-3
_Immune Responses to SARS-CoV-2_
Presenter: Akiko Iwasaki, PhD

Education Program
Wednesday, December 8
4:00 – 4:45 PM
Location: Georgia World Congress Center, C208-C210
_Management of Hemolytic Transfusion Reactions_
Presenter: Jeanne E. Hendrickson, MD

Training Program Director’s Workshop
Friday, December 10
9:00am- 12:00pm
Location: Omni Hotel at CNN Center, International Ballroom B-C
Moderator: Alfred Ian Lee, MD, PhD

ASH-a-palooza – Fellows’ Session
Friday, December 10
2:40 – 2:50 PM
3:00 – 3:10 PM
_Blood Drop: Wellness_
Speaker: Alfred Ian Lee, MD, PhD

Friday Satellite Symposia
Friday, December 10
3:00 – 6:00 PM
Location: Atlanta Marriott Marquis, Atrium A
_A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes_
Speaker: Amer M. Zeidan, MD

Location: Atlanta Marriott Marquis, Marquis Ballroom BCD
.Addressing Clinical Challenges in T-Cell Lymphomas Through Biomarker-Driven Therapy
Speaker: Francine Foss, MD
Oral Session  
Saturday, December 11  
9:30 – 11:00 AM  
**Location:** Georgia World Congress Center, B401-B402  
**Moderator:** Amer M. Zeidan, MD

**Location:** Georgia World Congress Center, B304-B305

602. **Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic and Molecular Responses in the Context of Targeted Therapies**

29 Beta-Catenin Forms Repressive Complexes with Ikzf1 and Ikzf3 to Orchestrate Tumor Suppression in B-Cell Malignancies

**Authors:** Kadriye Nehir Cosgun, PhD, Mark E. Robinson, PhD, Lai N. Chan, PhD, Matthew Hur, Etienne Leveille, MD, Joo Song, MD, Wing (John) C. Chan, MD and Markus Müschen, MD-PhD

637. **Myelodysplastic Syndromes – Clinical and Epidemiological: Low Risk Myelodysplastic Syndrome Prognosis and Treatment**

66 Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer Term Follow-Up of from the Ascertain Study

**Authors:** Guillermo Garcia-Manero, MD, James K McCloskey, MD, Elizabeth A. Griffiths, MD, Karen Yee, MD, Amer M. Zeidan, MD, Aref Al-Kali, MD, H. Joachim Deeg, MD, Prapti Patel, MD, Mitchell Sabloff, MSc, MD, FRCPC, Mary-Margaret Keating, MD, FRCPC, Kim-Hien Dao, DO, Nancy Zhu, MD, Nashat Y. Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Hagop Kantarjian, MD, Amy E. DeZern, MD, Casey L. O’Connell, MD, Gail J. Roboz, MD, Lambert Busque, MD, Richard A. Wells, MD, DPhil, Harshad Amin, MD, Jasleen K. Randhawa, MD, Brian Leber, MD, Yong Hao, MD, PhD, Harold N. Keer, MD, PhD, Mohammad Azab, MD and Michael R. Savona, MD

**Location:** Georgia World Congress Center, A411-A412

623. **Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Targeted Therapy in Low Grade Lymphoma**

43 First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab is Effective in Patients with Hcl

**Authors:** Jae H Park, MD, Eric S. Winer, MD, Scott F. Huntington, MD, MPH, Gottfried von Keudell, MD, PhD, Shreya Vemuri, Madhulika Shukla, Julie C Kinoshita, Victoria Falco, RN, BSN, Steven D. Gore, MD, Richard M. Stone, MD, Omar Abdel-Wahab, MD and Martin S. Tallman, MD

**Location:** Georgia World Congress Center, B312-B314

701. **Experimental Transplantation: Basic and Translational: The GI Tract and GVHD: Modeling the Structural and Microbial Elements of Disease**

86 Immune-Mediated Reprogramming of Intestinal Stem Cells Drives STAT1-Dependent Myc Expression and Epithelial Regeneration in GI-Gvhd

**Authors:** Shuichiro Takashima, MD, PhD, Roshan Sharma, Anastasiya Egorova, Jason Kttiyyara, Takahiro Ito, Winston Chang, Suze A Jansen, Chen Liu, MD, PhD, Caroline Lindemans, MD, PhD, Linas Mazutis, Nicolas Robine and Alan M Hanash, MD, PhD

88 Corticosteroid Treatment Impairs Epithelial Regeneration, Limiting Intestinal Recovery in Experimental Graft Vs Host Disease

**Authors:** Viktor Arnhold, MD, Suze A Jansen, Winston Chang, Govindarajan Thangavelu, PhD, Paola Vinci, PhD, Shuichiro Takashima, MD, PhD, Anastasiya
Egorova, Jason Kuttiyara, Marliek van Hoesel, Chen Liu, MD, PhD, Marco Calafiore, PhD, Bruce R. Blazar, MD, Caroline Lindemans, MD, PhD and Alan M Hanash, MD, PhD

**Location:** Georgia World Congress Center, B207-B208

903. **Health Services Research—Myeloid Malignancies**

**113 Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia**

**Authors:** Jan Philipp Bewersdorf, MD, George Goshua, MD, Kishan K Patel, MD, Rory M. Shallis, MD, Nikolai Podoltsev, MD, PhD, Scott F. Huntington, MD, MPH, and Amer M. Zeidan, MD

**Oral Session**

**Saturday, December 11**

12:00 – 1:30 PM

**Location:** Georgia World Congress Center, A411-A412

**634. Myeloproliferative Syndromes: Clinical and Epidemiological: Non-JAK inhibitor Therapies for Myelofibrosis**

**Moderator:** Nikolai Podoltsev, MD, PhD

905. **Outcomes Research—Lymphoid Malignancies: Lymphoma/CLL Real-World Data**

**182 Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis**

**Authors:** Mengyang Di, MD, PhD, Can Cui, MD, Shalin K. Kothari, MD, Amer M. Zeidan, MD, Nikolai Podoltsev, MD, PhD, Natalia Neparidze, MD, Rory M. Shallis, MD, Rong Wang, PhD, Xiaomei Ma, PhD, and Scott F. Huntington, MD, MPH

**Scientific Program**

**Saturday, December 11**

2:00 – 2:45 PM

**Location:** Georgia World Congress Center, Georgia Ballroom 1-3

**Immune Response to Old and New Enemies - Live Q&A**

**Presenter:** Akiko Iwasaki, PhD

**Oral/Poster Session**

**Saturday, December 11**

2:00 – 3:30 PM

**Location:** Georgia World Congress Center, B312-B314

**Podium Presentation**

906. **Outcomes Research—Myeloid Malignancies: Real World Outcomes**

**277 Venetoclax Plus Azacitidine (VEN-AZA) Vs. Intensive Chemotherapy (IC) As Induction for Patients with Acute Myeloid Leukemia (AML): Retrospective Analysis of an Electronic Medical Records (EMR) Database in the United States**

**Authors:** Amer M. Zeidan, MD, Daniel A. Pollyea, MD, MS, Uma Borate, MD, Alberto Vasconcelos, MD, Ravi Potluri, MBA, David Rotter, PhD, Zephirin Kiendrebeogo, Msc, PMP, Lona Gaugler, MSc, Gaetano Bonifacio, MD and Clara Chen, PhD
282 Contemporary “Real World” Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States
Authors: Rory M. Shallis, MD, Rong Wang, PhD, Amer M. Zeidan, MBBS, MHS, Scott F. Huntington, MD, MPH, Natalia Neparidze, MD, Mengyang Di, MD, PhD, Xiaomei Ma, PhD, and Nikolai A. Podoltsev, MD, PhD

Location: Georgia World Congress Center, Ballroom 1-2

612. Acute Lymphoblastic Leukemias: Clinical and Epidemiological: Clinical, genetic and societal risk factors impacting ALL outcomes
214 Epigenome-Wide Association Study of Acute Lymphoblastic Leukemia in Children with Down Syndrome
Authors: Shaobo Li, MBBS, Pagna Sok, PhD, Keren Xu, MPH, Ivo S Muskens, PhD, Natalina Elliott, PhD, Swe Swe Myint, Priyatama Pandey, MS, Helen M Hansen, BSc, Libby M Morimoto, PhD, Alice Y Kang, MPH, Catherine Metayer, MD, PhD, Xiaomei Ma, PhD, Beth A Mueller, PhD, Anindita Roy, MD, PhD, Irene Roberts, MD, PhD, Karen R Rabin, MD, PhD, Austin L Brown, MPH, PhD, Philip J. Lupo, Ph.D., M.P.H., Joseph L. Wiemels, PhD and Adam J. de Smith, PhD

Location: Georgia World Congress Center, B405-B407

634. Myeloproliferative Syndromes: Clinical and Epidemiological: Risk Stratification and Prognostication
240 European LeukemiaNet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database
Authors: Douglas Tremblay, MD, Andrew Srisuwananukorn, MD, Lukas Ronner, MD, Nikolai Podoltsev, MD, PhD, Jason Gotlib, MD, MS, Mark L. Heaney, MD, Andrew T. Kuykendall, MD, Casey L. O’Connell, MD, Jamile M. Shammo, MD, Angela Fleischman, MD, PhD, Ruben A. Mesa, MD, FACP, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, Erin Moshier, MS, Nicole Zubizarreta and John Mascarenhas, MD

Education Program
Saturday, December 11
4:00 – 4:45 PM
Location: Georgia World Congress Center, C208-C210
What’s New in the Transfusion Management of Sickle Cell Disease? Live Q&A
Speaker: Jeanne E. Hendrickson, MD

Thrombosis I
Saturday, December 11
4:00 – 5:30 PM
Location: Georgia World Congress Center, C202-C204
331. Thrombosis
Moderator: Alfred Ian Lee, PhD

Oral Session
Saturday, December 11
4:00 – 5:30 PM
Location: Georgia World Congress Center, B211-B212
636. Myelodysplastic Syndromes—Basic and Translational: Genomics and Novel Targets in MDS

321 U2AF1 Mutations Enhance Stress Granule Response in Myeloid Malignancies
Authors: Giulia Biancon, PhD, Poorval Joshi, PhD, Joshua T Zimmer, MS, Torben Hunck, Yimeng Gao, PhD, Mark D Lessard, MS, Edward Courchaine, PhD, Andrew ES Barentine, PhD, Martin Machyna, PhD, Valentina Botti, PhD, Ashley Qin, Rana Gbyli, MS, Amisha Patel, MS, Yuanbin Song, MD, Lea Kiefer, PhD, Gabriella Viero, PhD, Nils Neuenkirchen, PhD, Haifan Lin, PhD, Joerg Bewersdorf, PhD, Matthew D Simon, PhD, Karla M Neugebauer, PhD, Toma Tebaldi, PhD and Stephanie Halene, MD

Location: Georgia World Congress Center, B216-B217

501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational: Inflammation and Stress

298 ALKBH5 Modulates Hematopoietic Stem and Progenitor Cell Energy Metabolism through m^6a Modification-Mediated RNA Stability
Authors: Yimeng Gao, PhD Joshua T Zimmer, MS, Radovan Vasic, MD, MHS, Chengyang Liu, Rana Gbyli, MS, Shu-Jian Zheng, PhD, Amisha Patel, MS, Wei LIU, Raman Nelakanti, B.Sc., Yuanbin Song, MD, Giulia Biancon, PhD, Andrew Xiao, PhD, Sarah Slavoff, Ph.D., Matthew D Simon, PhD, Richard Flavell, PhD, Toma Tebaldi, PhD, Hua-Bing Li, Ph.D. and Stephanie Halene, MD

Poster Session I
Saturday, December 11
5:30 – 7:30 PM
Location: Hall B5 Georgia World Congress Center

508. Bone Marrow Failure

1113 Fanci-FANCD2 Promotes Genome Stability and DNA Repair By Down-Regulating BLM Helicase Activity
Authors: Fengshan Liang, PhD, Arvindhan Nagarajan, Manoj M Pillai, MD, Patrick Sung, PhD and Gary M. Kupfer, MD

1119 Compromised Host Stem Cell Competitiveness Affords Fanconi Stem Cell Engraftment in C-Kit Mutant Humanized Mice
Authors: Wei Liu, Yuanbin Song, MD, Rana Gbyli, Esen Sefik, Giulia Biancon, PhD, Yimeng Gao, PhD, William Philbrick, Amisha Patel, MS, Toma Tebaldi, PhD, Grzegorz Nalepa, Gary M. Kupfer, MD, Richard Flavell, PhD and Stephanie Halene, MD

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies

1243 Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial
Authors: Courtney D. DiNardo, MD, MSc, Pau Montesinos, PhD, MD, Andre C. Schuh, MD, Cristina Papayannidis, MD, PhD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCPath, Andrew H. Wei, MBBS, PhD, Amer M. Zeidan, MD, Iryna Bluemmert, PhD, Xin Yu, PhD, Maroof Hasan, MD, Patricia Martin-Regueira, MD and Stephane de Botton, MD, PhD

1244 Health-Related Quality of Life (HRQoL) during Treatment with Enasidenib (ENA) Plus Azacitidine (AZA) in Patients with Newly Diagnosed Mutant IDH2 (mIDH2) Acute Myeloid Leukemia (AML) Not Eligible for Intensive Chemotherapy (IC)
Authors: Courtney D. DiNardo, MD, MSc, Hartmut Dohner, MD, Amer M. Zeidan, MD, Andre C. Schuh, MD, Paresh Vyas, DPhil, FRCP, FRCPath, MRCP, MRCP, MRCPath, Eytan
M. Stein, MD, Andrew H. Wei, MBBS, PhD, Stephane de Botton, MD, PhD, Clara Chen, PhD, Jennifer Lord-Bessen, PhD, Patricia Martin-Regueira, MD, Frederik Lersch, PhD, Jing Gong, PhD, Shien Guo, PhD, Ling Shi, PhD and Pau Montesinos, PhD, MD

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological
1405 Response to Extracorporeal Photopheresis in Patients with Cutaneous T-Cell Lymphoma: A Retrospective Medical Chart Review
Authors: Michael Girardi, MD, PhD, Amy G Johnson, MD, Kacie Carlson, Xingyue Huang, PhD, Shelby Corman, MS, PharmD, Patrick Edmundson, Hrishikesh P Kale, PhD, MS, BPharm, Nifasha Rusibamayila and Francine M. Foss, MD

627. Aggressive Lymphomas: Clinical and Epidemiological
Authors: Nazila Shafagati, MD, Robert N. Stuver, MD, Leora Boussi, MD, Min Jung Koh, Allison Park, BS, Paul Bain, PhD, MS, Francine M. Foss, MD, Changyu Shen, PhD and Salvia Jain, MD

1457 A Multicenter, Real World Analysis of Primary Central Nervous System Lymphoma in Those with and without Human Immunodeficiency Virus
Authors: Christopher Dittus, DO, Natalie S Grover, MD, Tarsheen Sethi, MD, MBBS, Jonathon B. Cohen, MD, MS, Alfredo Voloschin, MD, Janhvi Rabadey, BS, Xianming Tan, PhD, Anne W. Beaver, MD and Steven I. Park, MD

637. Myelodysplastic Syndromes — Clinical and Epidemiological
1522 Evaluating Complete Remission with Incomplete Hematologic Recovery (CRh) As a Response Criterion in Myelodysplastic Syndromes (MDS)
Authors: Andrew M. Brunner, MD, Alexander Gavralidis, Najla Al Ali, MS, Rami S. Komrokji, MD, Amer M. Zeidan, MD and David A. Sallman, MD

1524 Analysis of Duration of Response, Exposure-Adjusted Safety and Progression to Acute Myeloid Leukemia (AML) for Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Receiving Luspatercept in the MEDALIST Study
Authors: Uwe Platzbecker, MD, Valeria Santini, Rami S. Komrokji, MD, Amer M. Zeidan, MD, Guillermo Garcia-Manero, MD, Rena J. Buckstein, MD, Shelonitda Rose, MD, Shannon Fabre, Dimana Miteva, Jennie Zhang, Aylin Yucel, Christina Hughes, PhD and Pierre Fenaux, MD, PhD

652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
1635 Outcomes Among Primary Refractory Multiple Myeloma Patients in the Era of Monoclonal Antibodies: The Yale Experience
Authors: Yuxin Liu, MD, Bohm Kywe, MD, Lake Crawford, Federico Lora, Noffar Bar, MD, Sabrina L. Browning, MD, Elan Gorshein, DO, JD, MPH, Terri L. Parker, MD and Natalia Neparidze, MD

721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities
1791 Clinical Experience in the Randomized Phase 3 Sierra Trial: Anti-CD45 Iodine (\[\text{I}^{131}\]) Apamistamab [Iomab-B] Conditioning Enables Hematopoietic Cell Transplantation with Successful Engraftment and Acceptable Safety in Patients with Active, Relapsed/Refractory AML Not Responding to Targeted Therapies
**Authors:** Boglarka Gyurkocza, MD, Rajneesh Nath, MD, **Stuart Seropian, MD,** Hannah Choe, MD, Mark R. Litzow, MD, Nebu V. Koshy, Patrick Stiff, MD, Camille Abboud Sr., MD, Benjamin Tomlinson, MD, Sunil Abhyankar, MD, Parameswaran Hari, Zaid S. Al-Kadhimi, MD, George L. Chen, MD, Mitchell Sabloff, MSc, MD, FRCP, Johnnie J. Orozco, MD, PhD, James M. Foran, MD, Partow Kebriaei, MD, Katarzyna Joanna Jamieson, MD, Margarida Magalhaes Magalhaes-Silverman, Koen van Besien, MD, PhD, Michael W. Schuster, MD, Arjun Law, MD, Moshe Levy, MD, Hillard M Lazarus, MD, Sergio A Giralt, MD, Mark S. Berger, MD, Jennifer A Spross, MA, Avinash G Desai, MD, Vijay Reddy, MD, PhD and John M. Pagel, MD, PhD

---

**902. Health Services Research—Lymphoid Malignancies**

*1918 Functional Status and Therapy for Nursing Home Residents with Diffuse Large B-Cell Lymphoma: A Population-Based Study*

**Authors:** Mengyang Di, MD, PhD, Adam J. Olszewski, MD, Tamra Keeney, DPT, PhD, Emmanuelle Belanger, PhD, and Orestis A. Panagiotou, MD, PhD

---

**905. Outcomes Research—Lymphoid Malignancies**

*1973 Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States*

**Authors:** Natalia Neparidze, MD, Krystal W. Lau, Xiaoliang Wang, PhD, MPH, Amy J. Davidoff, PhD, Scott F. Huntington, MD, MPH, Omer Hassan Jamy, MD, Gregory Calip, PhD, Harsh Shah, DO, Deborah M. Stephens, Rebecca A. Miksd, MD, MPH, Ravi Parikh, MD, Samuel Takvorian, Natalia Neparidze, MD and Erlene K Seymour, MD

---

**Oral Session**

**Sunday, December 12**

9:30 – 11:00 AM

**Location:** Georgia World Congress Center, B216-B217

**603. Oncogenes and Tumor Suppressors: Basic: Aberrant signal strength and novel mechanisms in lymphoid and myeloid malignancies**

*355 Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies*

**Authors:** Jaewoong Lee, Mark E. Robinson, PhD, Ning Ma, Ph.D, Kohei Kume, PhD, Dewan Artadji, Teresa Sadras, PhD, Kadiyee Nehir Cosgun, PhD, Huimin Geng, PhD, Elisabeth M. Paietta, PhD, Maike Buchner, PhD, Nagarajan Vaidehi, PhD, David M. Weinstock, MD and Markus Müschen, MD-PhD

---

**Oral Session**

**Sunday, December 12**

12:00 – 1:30 PM

**Location:** Georgia World Congress Center, Thomas Murphy Ballroom 1-2

**904. Outcomes Research—Non-Malignant Conditions: Sickle Cell Disease Management and Outcomes Across the Lifespan**

**Moderator:** Cecelia Calhoun, MD, MPH, MBA
**Location:** Georgia World Congress Center – B405-B407

**201. Granulocytes, Monocytes, and Macrophages: Production and Functions**

**434 Lymphocyte Cytosolic Protein 1 I232F Mutation Impairs Granulocytic Proliferation with a G2/M Block in Severe Neutropenia**

**Authors:** Upendra Mahat, MD, MBBS, Bhavuk Garg, PhD, Hrishikesh M Mehta, PhD, Heesun J. Rogers, MD, Andrei Ivanov, PhD, Chao-Yie Yang, Aron Flagg, MD and Seth J. Corey, MD, MPH

**Location:** Georgia World Congress Center, Georgia Ballroom 1-3

**627. Aggressive Lymphomas: Clinical and Epidemiological: Clinical Management of Aggressive B cell NHL**

**455 High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers**

**Authors:** Adam Zayac, MD, Daniel J Landsburg, MD, Mitchell Hughes, PharmD, Emily C. Ayers, MD, Mark Girton, MD, Marie Hu, MD, Amy Beckman, MD, Shaoying Li, L. Jeffrey Medeiros, MD, Habibe Kurt, MD, Jose Sandoval-Sus, MD, M. Ali Ansari-Lari, MD, Shalin K. Kothari, MD, Anna Kress, MD, Mina L. Xu, MD, Pallawi Torka, MD, Suchitra Sundaram, MD, Stephen D. Smith, MD, Kikkeri N Naresh, MD, MBBS, Yasmin Karimi, MD, Narendranath Epperla, MD, MS, David A. Bond, MD, BS, Andrew M. Evens, DO, MMS, Karan Pandya, MD, Seema G Naik, MD, Manali Kamdar, MD, Brad Haverkos, MD, MPH, MS, Reem Karmali, MD, Msc, Timothy Seijung Oh, MD, Julie M. Vose, MD, MBA, Heather Nutsch, Paul Rubinstein, MD, Amina Chaudhry, MD and Adam J. Olszewski, MD

**Oral Session**

**Sunday, December 12**

4:30 – 6:00 PM

**Location:** Georgia World Congress Center, Thomas Murphy Ballroom 3-4

**627. Aggressive Lymphomas: Clinical and Epidemiological: Real World evidence for CAR-T Management I**

**530 Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cell) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction**

**Authors:** Frederick L. Locke, MD, Caron Jacobson, MD, Long Ma, PhD, Hua Dong, PhD, Zhen-Huan Hu, PhD, Tanya Siddiqi, MD, Sairah Ahmed, MD, Armin Ghobadi, MD, David B. Miklos, MD, PhD, Yi Lin, MD, PhD, Miguel-Angel Perales, MD, Matthew A. Lunning, DO, FACP, Megan M. Herr, PhD, Brian T. Hill, MD, Siddhartha Ganguly, MD, Abu-Sayeeff Mirza, MD, MPH, Sarah Nikiforow, MD, PhD, Hairong Xu, MD, PhD and Marcelo C Pasquini, MD, MS

**Location:** Georgia World Congress Center, B211-B212


**537 Venetoclax and Azacitidine in the Treatment of Patients with Relapsed/Refractory Myelodysplastic Syndrome**

**Authors:** Amer M. Zeidan, MD, Uma Borate, MD, Daniel A. Pollyea, MD, MS, Andrew M. Brunner, MD, Fernando Roncolato, Jacqueline S. Garcia, MD, Robin J Filshie, MBChB, PhD, FRACP, FRCPath, Olatoyosi Odenike, MD, Anne-Marie Watson, Ravi Krishnadasan, MD, Ashish Bajel, MBBS, FRACP, FRCPA, Kiran Naqvi, MD, Jiuhong Zha, PhD, Leah Hodgad, PhD, Ying Zhou, PhD, David Hoffman, Steve Kye and Guillermo Garcia-Manero, MD
Poster Session II
Sunday, December 12
6:00 – 8:00 PM
Location: Georgia World Congress Center, Hall B5

321. Coagulation and Fibrinolysis: Basic and Translational
Prothrombotic Phenotype of a Protein S Mutant Lacking Anticoagulant Activity
Authors: Stephanie Springborn, MS, Sourav Ghosh, PhD, Marie L Schulte, PhD, Carla Rothlin, PhD and Brian R Branchford, MD

503. Clonal Hematopoiesis, Aging and Inflammation
Characteristics and Clinical Outcome of Patients with Clonal Cytopenias of Undetermined Significance: A Large Retrospective Multi-Center International Study
Authors: Zhuoer Xie, MD, MS, Meredith C. Hyun, MS, Rami S. Komrokji, MD, Amer M. Zeidan, MD, Yazan F. Madanat, MD, Joshua F. Zeidner, MD, Catherine C. Coombs, MD, Elizabeth A. Griffiths, MD, Catherine Lai, MD, MPH, Ashwin Kishtagari, MBBS, James M. Foran, MD, Talha Badar, MD, Cecilia Arana Yi, MD, Pinkal Desai, MD, MPH, Lionel Ades, MD, PhD, Afaf Osman, MD, Justin Taylor, MD, H. Joachim Deeg, MD, Andrew M. Brunner, MD, Hetty E. Carraway, MD, MBA, Najla Al Ali, MS, Jan Philipp Bewersdorf, MD, Thomas Prebet, MD, PhD, Abhay Singh, MBBS, MPH, Charlton Tsai, MD, Namrata Chandhok, MD, Deborah Soong, MD, Mrinal M. Patnaik, MBBS, Michael R. Savona, MD and Aref Al-Kali, MD

602. Disordered Gene Expression and Epigenetics in Hematologic Malignancies: Basic
Authors: Cassandra Love, Raju Pillai, MD, Sarah L. Ondrejka, DO, Govind Bhagat, M.D., Amy Chadburn, MD, Matthew McKinney, MD, Jean L. Koff, MD, MSc, Dina Sameh Soliman, MD, PhD, MBBS, MSc, Magdalena Czader, MD, PhD, Abner Louissaint Jr., MD, PhD, Shaoying Li, Choon Kiat Ong, PHD, Amir Behdad, MD, Andrew M. Evans, DO, MMSc, Yasodha Natkunam, MD, PhD, Peter H. Norgaard, MD, PhD, Sirpa Leppa, MD, PhD, Eric Tse, MBBS, PhD, FRCPath, Jennifer R Chapman, MD, Catalina Amador, MD, Yuri Fedoriw, MD, Agata M. Bogusz, MD, PhD, Andrew G Evans, MD, PhD, Rashmi S. Goswami, MD, PhD, Ridas Juskevicius, MD, Mina L. Xu, MD, Kikkeri N Naresh, MD, MBBS, Barbara Xiong, Adam Snowden, Anabel Thurman, Eileen Smith, Tushar Dave, MS, Rachel Kositsky, BS, Devang Thakkar, Veronica Russell, Caroline J Roth, MS and Sandeep Dave

605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms
Pharmacological Targeting of PI3K-Dependent Central Tolerance Mechanisms in Refractory Pre-Germinatal Center B-Cell Malignancies
Authors: Kohei Kume, PhD, Jaewoong Lee, Lai (Linda) N. Chan, PhD, Mark E. Robinson, PhD, Kadriye Nehir Cosgun, PhD, Eric Meffre, PhD and Markus Müschen, MD-PhD

615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies
Outcome with Intensive Chemotherapy Compared to Hypomethylating Agent-Based Induction in Patients Aged 70 Years or Older with Newly Diagnosed Favorable Risk Acute Myeloid Leukemia
Authors: Somedeb Ball, MD, Akriti G Jain, MD, Luis E. E. Aguirre, MD, Najla Al Ali, MS, Jan Philipp Bewersdorf, MD, Alexander Hayden, Alexa J. Siddon, MD, Jillian Lykon, PharmD, Ellen Madarang, PharmD, David A. Sallman, MD, Eric Padron, MD, Kendra Sweet, MD, Jeffrey E. Lancet, MD, Justin M Watts, MD, David M Swoboda, MD, Daniel A. Pollyea, Amer M. Zeidan, MD and Rami S. Komrokji, MD

624. Hodgkin Lymphomas and T/NK cell Lymphomas: Clinical and Epidemiological
2441 No Difference in Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis
Authors: Pamela Allen, MD, Subir Goyal, PhD, Irl Brian Greenwell, MD, Jane Scribner, MD, Sunil Rangarajan, MD, Amitkumar Mehta, MD, Colin Burke O'Leary, MA, Tim Niyogusaba, BA, Auris Huen, MD, Jeffrey M. Switchenko, PhD, MS, Erica Shantha Tarabadkar, MD, Amy Ayers, MPH, Shalini Krishnasamy, MD, Pierluigi Porcu, MD, Tarsheen Sethi, MD, MSCI, Swaminathan P Iyer, MD and Mary Jo Lechowicz, MD

627. Aggressive Lymphomas: Clinical and Epidemiological
2533 A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) – Valentine-PTCL01
Authors: Francine M. Foss, MD, Pierluigi Porcu, MD, Steven M. Horwitz, MD, Koji Izutsu, MD, PhD, Kenji Ishitsuka, MD, PhD, Kazunobu Kato, MD, PhD, Jin Jin, PhD, Yining Du, PhD and Ai Inoue, MD, PhD

634. Myeloproliferative Syndromes: Clinical and Epidemiological
2583 Novel Machine Learning Algorithm Predicts Disease Progression in Polycythemia Vera (PV) with Readily-Available Baseline Characteristics
Authors: Andrew Srisuwananukorn, MD, Beth Percha, PhD, Ghaith Abu-Zeinah, MD, Joseph Scandura, MD, PhD, Spencer Krichevsky, MS, Elwood Taylor III, BS, Richard T. Silver, MD, Santiago Thibaud, MD, Lukas Ronner, MD, Nikolai Podoltsev, MD, PhD, Jason Gotlib, MD, MS, Mark L. Heaney, MD, Andrew T. Kuykendall, MD, Casey O'Connell, MD, Jamile M. Shammo, MD, Angela Fleischman, MD, PhD, Ruben A. Mesa, MD, FACP, Abdulraheem Yacoub, MD, Ronald Hoffman, MD, John Mascarenhas, MD and Douglas Tremblay, MD

636. Myelodysplastic Syndromes—Basic and Translational
2592 Clonal Compositions Involving Epigenetic Regulator Gene Mutations in Clonal Hematopoiesis, Clonal Cytopenias of Undetermined Significance and Chronic Myelomonocytic Leukemia
Authors: Zhuoer Xie, MD, MS, Gina Campestri, MD, Terra Lasho, PhD, Christy Finke, BS, Marissa Li, MD, Moritz Binder, MD, Keith Robertson, PhD, Jenna Fernandez, PhD, Meredith C. Hyun, MS, Rami S. Komrokji, MD, Amer M. Zeidan, MD, Jan Philipp Bewersdorf, MD, Joshua F. Zeidner, MD, Catherine C. Coombs, MD, Yazan F. Madanat, MD, Elizabeth A. Griffiths, MD, Catherine Lai, MD, MPH, Michael R. Savona, MD, Mithun V. Shah, MD, PhD, Mark R. Litzow, MD, Ayalew Tefferi, MD, Abhishek A. Mangaonkar, MBBS, Naseema Gangat, M.B.B.S, Aref Al-Kali, MD and Mrinal M. Patnaik, MD, MBBS

732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies
Non-Relapse Mortality in TP53-Mutated MDS/AML - a Multi-Center Collaborative Study

**Authors:** Michael T. Byrne, DO, Tony J Kurian, MD, Dilan A Patel, MD, Roni Tamari, MD, Sanghee Hong, MD, Haitham Abdelhakim, MD, Victoria Klein, Patricio Rojas, MD, Raksha Madhavan, MD, Andrew Kent, MD, PhD, Aaron C. Logan, MD, PhD, Catherine J. Lee, MD, Muhammad Husnain, MD, Benjamin M Manning, MD, PhD, Nicholas P. Tschernia, MD, Ajoy L. Dias, MD, Daniel Margalski, DO, Benjamin Goldenson, MD, PhD, Nathalie Byrne, APRN, Heidi Chen, PhD, Kseniya Petrova-Drus, MD, PhD, Salyka M. Sengsayadeth, MD, Aaron M Goodman, Dianna S. Howard, MD, William A. Wood, MD, MPH, Saar Gill, MD, PhD, Antonio M. Jimenez, MD, MSc, Jonathan A. Gutman, MD, Lohith Gowda, MD, Leland Metheny III, MD, Bhavana Bhatnagar, DO, Betty K. Hamilton, MD, Asmita Mishra, MD and Michael R. Savona, MD

901. Health Services Research—Non-Malignant Conditions

**2974 Implementing a Full Time Equivalent-Supported Hematology/Oncology Fellowship Core Faculty Program May Improve Faculty Engagement in Education, Mentorship, and Recruitment**

**Authors:** Jana Christian, MD, Lucilina Gilkes, Sarah Goldberg, MD, Michael Hurwitz, MD, PhD, Nikolai Podoltsev, MD, PhD and Alfred Ian Lee, MD, PhD

2977 Diversity, Equity, and Inclusion in Hematology and Oncology Fellowship Programs

**Authors:** Michael Mankbadi, MD, Lidet Alemu, Afiya Bey, Nathan T. Connell, MD, Lisa Fanning, Patricia Frustace, Inginia Genao, MD, Janet Hafler, EdD, Ann S. LaCasce, MD, MMSc, Tiffany Lin Lucas, MD, Ariela L. Marshall, MD, Jodi Mones, MD, Martina C Murphy, MD, Rakhi P. Naik, MD, Nikolai Podoltsev, MD, PhD and Alfred Ian Lee, MD, PhD

903. Health Services Research—Myeloid Malignancies

**3018 Implementation of Inpatient Palliative Care Consultation Triggers and Its Impact on Healthcare Use in Patients with Relapsed/Refractory Acute Myeloid Leukemia**

**Authors:** Jenny J Xiang, Elizabeth Horn Prsic, MD, Kerin B Adelson, MD and Thomas Prebet, MD, PhD

**3020 Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey**

**Authors:** Oreofe O. Odejide, MD, MPH, Scott F. Huntington, MD, MPH, Eleanor Shi, B.S., Kimberly S. Johnson, MD, James A. Tulsky, MD and Gregory A. Abel, MD, MPH

Oral Session

**Monday, December 13**

10:30 – 12:00 PM

**Location:** Georgia World Congress Center, Hall A1

**Moderator:** Tarsheen Sethi, MD, MSCI

624. Hodgkin Lymphomas and T/NK cell Lymphomas: T/NK Cell Lymphoma Relapsed Therapy

**Authors:** Thomas E. Witzig, MD, Lubomir Sokol, MD, PhD, Won Seog Kim, MD, PhD, Fátima de la Cruz Vicente, MD, Dolores Caballero, MD, Ranjana Advani, MD, Raquel
de Oña, Ana Marin Niebla, MD, María José Terol, MD PhD, Domingo Domenech Eva, MD, Nawal Bendris, Ph.D., Julie Mackey Ahsan, M.S., Mollie Leoni, M.D. and Francine M. Foss, MD

**Location:** Georgia World Congress Center – B405-B407

### 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Mechanisms of Treatment Resistance

#### 616 Leveraging Pathway-Interference to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia

**Authors:** Lai N. Chan, PhD, Mark A. Murakami, MD, MA, MMSc, Christian Hurtz, PhD, Kohei Kume, PhD, Jaewoong Lee, Kadiyie Nehir Cosgun, PhD, Huimin Geng, PhD, Shai Izraeli, MD, David M. Weinstock, MD and Markus Müschen, MD-PhD

**Location:** Georgia World Congress Center – B407

### 311. Disorders of Platelet Number or Function: Clinical and Epidemiological: Thrombopoietin Receptor Agonists and Other Clinical Topics in Thrombocytopenia

#### 586 Sars-Cov-2 Vaccination in Patients with Pre-Existing Immune Thrombocytopenia

**Authors:** Eun-Ju Lee, MD, Marina Beltrami Moreira, MD, PhD, Hanny Al-Samkari, MD, Adam Cuker, MD, MS, Jennifer MacWhirter - DiRaimo, Terry B. Gernsheimer, MD, Alexandra Kruse, Craig M. Kessler, MD, Caroline Kruse, Andrew D Leavitt, MD, Alfred Ian Lee, MD, PhD, Howard A. Liebman, MD, Adrian C. Newland, Ashley E. Ray, FNP, Michael D Tarantino, MD, Jecko Thachil, MBBS, David J. Kuter, MD, DPhil, Douglas B. Cines, MD and James B Bussel

### Oral Session

**Monday, December 13**

2:45 – 4:15 PM

**Location:** Georgia World Congress Center – Georgia Ballroom 1-2

**Moderator:** Rory M. Shallis, MD

**Location:** Georgia World Congress Center – B206

### 901. Health Services Research—Non-Malignant Conditions: Conquering Challenges in Hematology

#### 751 Cost-Effectiveness of Second-Line Therapies in Adult Patients with Chronic Immune Thrombocytopenia

**Authors:** George Goshua, MD, Pranay Sinha, MD2, Lauren Pischel, MD, Alfred Ian Lee, MD, PhD and Adam Cuker, MD, MS

**Location:** Georgia World Congress Center – Georgia Ballroom 1-3

### 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Targeted Therapies and Novel Therapies

#### 698 Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia

**Authors:** Jorge E. Cortes, MD, Jordi Esteve, MD, PhD, Ashish Bajel, MBBS, FRCPA, Karen Yee, MD, Thorsten Braun, MD, PhD, Stephane De Botton, Pierre Peterlin, MD, Christian Recher, MD, PhD, Xavier Thomas, MD, PhD, Justin Watts, MD, Montserrat Arnan Sangerman, MD PhD, Antonio Curti, MD, PhD, Carolyn Grove, MBBS, PhD, Brian A. Jonas, MD, PhD, FACP, Francesco Lanza, MD, Olivier Legrand, MD, PhD, Pau Montesinos, PhD, MD, Prapti Patel, MD, Thomas Prebet, MD, PhD,
**Location:** Georgia World Congress Center – B302-B303

618. **Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Novel therapeutic targets and pre-clinical studies**  
**Moderator:** Lai N. Chan, PhD

**Thrombosis II**  
**Monday, December 13**  
4:30 – 6:00 PM  
**Location:** C101 Auditorium  

331. **Thrombosis**  
777 **Proteomic Profiles in Patients with Thrombosis Due to COVID-19 Are Distinct from Non-COVID-19 Thrombosis**  
**Authors:** Daria V Madeeva, MD, Kelly Borges, MS, Marcus Shallow, Prerak V Juthani, BA, Stephen Y Wang, MD MPH, Akash Gupta, MD, Hyung J. Chun, MD, Alfred Ian Lee, MD, PhD and Alexander B Pine, MD PhD

**Oral Session**  
**Monday, December 13**  
4:30 – 6:00 PM  
**Location:** Georgia World Congress Center, B401-B402  

102. **Iron Homeostasis and Biology: Disorders of Iron and Heme and Novel Treatments**  
**Moderator:** Karin E. Finberg, MD, PhD  
759 **Bone Marrow Sinusoidal Endothelial Cells Are a Site of Fgf23 Upregulation in Iron Deficiency Anemia**  
**Authors:** Xiuqi Li, PhD, Larisa Lozovatsky, MS, Jackie A. Fretz, PhD and Karin E. Finberg, MD, PhD

605. **Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Targeted Agents**  
792 **Identification of BCL6 As Synthetic Lethality in RAS-Driven B-Cell Transformation**  
**Authors:** Lai N. Chan, PhD, Christian Hurtz, PhD, Etienne Leveille, MD, Kohei Kume, PhD, Mark E. Robinson, PhD, Huimin Geng, PhD, Kadriye Nehir Cosgun, PhD and Markus Müschen, MD-PhD

613. **Acute Myeloid Leukemia: Clinical and Epidemiological: Practice-changing studies**  
797 **Multicenter Analysis of Treatment and Outcomes for Patient with TP53 Mutated AML in the Era of Novel Therapies: Significant Impact of Allogeneic Stem Cell Transplantation on Survival**  
**Authors:** Talha Badar, MD, Mark R. Litzow, MD, Rory M. Shallis, MD, Jan Philipp Bewersdorf, MD, Antoine Saliba, MD, Guilherme sacchi De Camargo Correia, MD, Maximilian Stahl, MD, Aaron D Goldberg, MD, PhD, Ehab L. Atallah, MD and James M. Foran, MD
**Oral Session**

**Monday, December 13**

6:15 – 7:45 PM

**Location:** Georgia World Congress Center, B302-B303

**605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Novel Targets and Therapeutics**

*868 Identification of a Conserved Intracellular Loop (CIL) Structure That Scaffolds PIP3 to Amplify Oncogenic Signaling during Malignant B-Cell Transformation*

**Authors:** Jaewoong Lee, Mark E. Robinson, PhD, Ning Ma, Ph.D, Teresa Sadras, PhD, Kadriye Nehir Cosgun, PhD, Lai N. Chan, PhD, Kohei Kume, PhD, Andrei Thomas-Tikhonenko, PhD, David M. Weinstock, MD, Michael S. Diamond, PhD, Nagarajan Vaidehi, PhD and Markus Müschen, MD-PhD

**Location:** Georgia World Congress Center, Hall C1

**624. Hodgkin Lymphomas and T/NK cell Lymphomas: Hodgkin Lymphoma Clinical Outcomes Data**

*881 The Evolution of Children’s Oncology Group Hodgkin Lymphoma Trials: Predicted Impact on Late Cardiac Toxicity*

**Authors:** Andrea C. Lo, MD, MPH, FRCPC, Amy Liu, PhD, Qi Liu, M.Sc, Yutaka Yasui, PhD, Sharon M. Castellino, MD, MSc, Kara M. Kelly, MD, Alex F. Herrera, MD, Jonathan W. Friedberg, MD, Debra L. Friedman, MD, Cindy L. Schwartz, MD, Samuel Bergeron-Gravel, MD, Hitesh Dama, BSc, Kenneth B. Roberts, MD, Louis S. Constine, MD and David Hodgson, MD, MPH

**Location:** Georgia World Congress Center, Thomas Murphy Ballroom 3-4

**721. Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities; Potential Factors Affecting Outcomes of Variable Transplant Settings**

*907 Major ABO Incompatibility Significantly Influences the Survival and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Leukemia – CIBMTR Analysis*

**Authors:** Guru Subramanian Guru Murthy, MD, Brent R. Logan, PhD, Stephanie Bo-Subait, MPh, Amer Beitingjianeh, Steven Devine, MD, Nosha Farhafdar, MD, Lohith Gowda, MD, Shahrukh Hashmi, MD, MPH, Hillard Lazarus, Sunita Nathan, MD, Akshay Sharma, MBBS, Jean A. Yared, MD, Heather E. Stefanski, MD, PhD, Michael A. Pulsipher, MD, Jack W. Hsu, Galen E. Switzer, PhD, Sandhya R. Panch and Bronwen E. Shaw, MD, PhD

**Poster Session III**

**Monday, December 13**

6:00 – 8:00 PM

**Location:** Hall B5 Georgia World Congress Center

**501. Hematopoietic Stem and Progenitor Cells and Hematopoiesis: Basic and Translational**
3270 Single-Cell Tracking By Time Lapse Imaging Confirms Thrombopoietin Promotes Megakaryocytic-Erythroid Progenitor Self Renewal, but Does Not Instruct Lineage Commitment

Authors: Vanessa M Scanlon, PhD, Maria Kochugaeva, PhD, Betty M Lawton, PhD, Juliana Xavier-Ferrucio, PhD, Elaine Kang, MS, Nicole M Eskow, MS, Yi-Chien Lu, PhD, Nayoung Kwon, BS, Anisha Laumas, Matthew Cenci, BS, Kalyani Lawrence, Katie Barden, Shannon M Laruel, Fiona Reed, Gabriela Pena-Carmona, Ashley Ubelohde, MS, June P Lee, BS, Shakti Boobalan, Yvette Oppong, BS, Rachel Anderson, Colby Maynard, Kaylie Sahirul, BS, Callista Lajeune, Varsha Ivathraya, Tiffany Addy, Patricia Sanchez, Colin Holbrook, Andrew Tri Van Ho, PhD, Helen M. Blau, PhD, Andre Levchenko, PhD and Diane S. Krause, MD, PhD

613. Acute Myeloid Leukemias: Clinical and Epidemiological

3371 Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Authors: Amer M. Zeidan, MD, Jan Philipp Bewersdorf, MD, Vanessa Hasle, Ethan G. Thompson, PhD, Daniel Lopes de Menezes, PhD, Shelonitda Rose, MD, Isaac Boss and Brian Fox

614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies

3407 Maximal Tolerated Dose Determined for Venetoclax in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory Ph-Negative T-Cell or B-Cell Acute Lymphoblastic Leukemia: Results of Phase 1 Portion of ECOG-ACRIN EA9152

Authors: Neil Palmisiano, MD, Ju-Whei Lee, David F. Claxton, MD, Elisabeth Paietta, PhD, Hassan B. Alkhateeb, MD, Jae H Park, MD, Nikolai Podoltskev, MD, PhD, Ehab L. Atallah, MD, Dale G Schaar, MD, PhD, Shira Dinner, MD, Jonathan Webster, MD, Selina M. Luger, MD, FRCPC, and Mark R. Litzow, MD

617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis

3431 Predictive Biomarkers of Response to the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Decitabine in Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Authors: Amer M. Zeidan, MD, Maya Ridinger, PhD, Peter J.P. Croucher, PhD, Errin Samuëlsz, Mark Erlander, PhD, Katherine L. Ruffner, MD and Eunice S. Wang, MD

623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological

3534 Phase 1b/2 Study of Cirmtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)

Authors: Hun Ju Lee, Michael Choi, Tanya Siddiqi, MD, Jacqueline Barrientos, MD, MS, William G. Wierda, Iris Isufi, MD, Joseph Tuscano, Nicole Lamanna, MD, Suki Subbiah, MD, Jean L. Koff, MD, MSc, Lori A. Leslie, MD, Alec Goldenberg, MD, Gina G Chung, MD, James B. Breitmeyer, MD, PhD, Salim Yazji, MD, Yao Wang, MD, MS, Michael Wang, MD, Catriona Jamieson, MD, PhD and Thomas J. Kipps, MD, PhD

632. Chronic Myeloid Leukemia: Clinical and Epidemiological

3613 Minimal Toxicity Seen When Pembrolizumab Is Added to Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia and Persistently Detectable
Minimal Residual Disease: Early Results from an Ongoing Phase II Trial (ECOG-ACRIN EA9171)

Authors: Amer M. Zeidan, MD, Kevin Roopcharan, Jerry P. Radich, MD, Jan Philipp Bewersdorf, MD, Vijaya R. Bhatt, MD; MS, Elad Sharon, MD, MPH, Richard F. Little, MD, MPH, Steven D. Gore, MD, Anne Caldwell, Selina M. Lugger, MD, FRCPC and Mark R. Litzow, MD

637. Myelodysplastic Syndromes — Clinical and Epidemiological

3682 Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Authors: Michael R. Savona, MD, James K McCloskey, MD, Elizabeth A. Griffiths, MD, Karen Yee, MD, Amer M. Zeidan, MD, Aref Al-Kali, MD, H. Joachim Deeg, MD, Prapti Patel, MD, Mitchell Sabloff, MSc, MD, FRCPC, Mary-Margaret Keating, MD, FRCPC, Kim-Hien Dao, DO, Nancy Zhu, MD, Nashat Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Hagop Kantarjian, MD, Amy E. DeZern, MD, Casey L. O’Connell, MD, Gail J. Roboz, MD, Lambert Busque, MD, Richard A. Wells, MD, DPhil, Harshad Amin, MD, Jasleen K. Randhawa, MD, Brian Leber, MD, Yong Hao, MD, PhD, Harold N. Keer, MD, Mohammad Azab, MD and Guillermo Garcia-Manero, MD

3701 Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting

Authors: Jan Philipp Bewersdorf, MD, Wei Wei, MD, Anna Jaiani, Prital Patel, Rajni Mehta, Natalia Neparidze, MD, Rory M. Shallis, MD, Nikolai Podoltsev, MD, PhD, Andrew M. Brunner, MD, and Amer M. Zeidan, MD

642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological

3748 Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial

Authors: Javier Pinilla Ibarz, MD, PhD, Wojciech Jurczak, MD, PhD, Suman Kambhampati, MD, Ewa Lech Maranda, MD, PhD, Tomasz Wróbel, MD, PhD, Jeff P. Sharman, MD, Syed F. Zafar, MD, Marc Hoffmann, MD, Scott F. Huntington, MD, MPH, Ryan Jacobs, MD, Osnat Bairey, MD, Chris Rowland, PhD, Hari P. Miskin, MSc, Peter Sportelli, BS, Michael S. Weiss, Owen A. O’Connor, MD, PhD and Ian W. Flinn, MD, PhD

3726 Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Authors: Ryan Jacobs, MD, Wojciech Jurczak, MD, PhD, Ian W. Flinn, MD, PhD, Sebastian Grosicki, MD, PhD, Krzysztof Giannopoulos, MD, PhD, Tomasz Wróbel, MD, PhD, Syed F. Zafar, MD, Jennifer L. Culterra, MD, Suman Kambhampati, MD, Alexey V. Danilov, MD, PhD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD, MPH, Javier Pinilla Ibarz, MD, PhD, Jeff P. Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, John M. Pagel, MD, PhD, Monika Dlugosz-Danecka, MD, PhD, Nilanjana Ghosh, MD, PhD, Kathryn S. Kolibaba, MD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O’Connor, MD, PhD, Michael S. Weiss and John G. Gribben, MD, DSc, FRCP, FMedSci, FRCPPath

902. Health Services Research—Lymphoid Malignancies

4024 Physical Therapy Utilization Among Hospitalized Patients with Pediatric Acute Lymphoblastic Leukemia
Authors: Rozalyn L. Rodwin, Xiaomei Ma, PhD, Kirsten K. Ness, PT, PhD, Nina S. Kadan-Lottick, MD, MSPH and Rong Wang, PhD

4026 Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies

Authors: Oreofe O. Odejide, MD, MPH, Scott F. Huntington, MD, MPH, Thomas M. Kuczmarski, MD, Eleanor Shi, B.S., James A. Tulsky, MD and Gregory A. Abel, MD, MPH

905. Outcomes Research—Lymphoid Malignancies

4092 Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period

Authors: Natalia Neparidze, MD, Rong Wang, PhD, Amer M. Zeidan, MD, Nikolai Podoltsev, MD, PhD, Rory M. Shallis, MD, Xiaomei Ma, PhD, Amy J. Davidoff, PhD, and Scott F. Huntington, MD, MPH

4121 Racial and Age-Related Differences in Impacts of High-Risk Cytogenetic Abnormalities on Survival in Multiple Myeloma in a Nationwide Electronic Health Record-Derived Database

Authors: Gregory S Calip, PharmD, MPH, PhD, Mustafa S Ascha, PhD, MS, Xiaoliang Wang, PhD, MPH, Amy E Pierre, MSN, ANP-BC, Kathleen Maignan, MSN, NP, Niquelle B Wadé, PhD, Siyang Leng, MD, MS, Erlene K Seymour, MD, Brian C-H Chiu, PhD, Karen Sweiss, PharmD, Pritesh R Patel, MB, ChB and Natalia Neparidze, MD
Committees/Membership/Awards

ASH Committee On Practice
Liaison: Kelsey Martin, MD

ASH Committee On Training
Member: Alfred Ian Lee, MD, PhD

ASH Abstract Achievement Award
Giulia Biancon, PhD, Yimeng Gao, PhD, Wei Liu, PhD